The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

Jin-Yan Li, Zhi You, Qiong Wang, Zhi-Jian Zhou, Ye Qiu, Rui Luo, Xing-Yi Ge, Jin-Yan Li, Zhi You, Qiong Wang, Zhi-Jian Zhou, Ye Qiu, Rui Luo, Xing-Yi Ge

Abstract

At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV.

Keywords: 2019-nCoV; ACE2; Bat; Pneumonia; SARS-CoV; Spike.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Figures

Fig. 1
Fig. 1
The evolutionary position of 2019-nCoV. The phylogenetic tree was constructed based on the complete genomic sequences of 2019-nCoV and related CoVs by using the neighbor-joining (NJ) method with 1000 bootstrap. The novel 2019-nCoV detected strains were indicated in bold with solid squares. Abbreviations are as follows: SARSr coronavirus, SARS-related coronavirus. The accession numbers of CoVs were showed in the figure. Bootstrap values above 50 were shown.
Fig. 2
Fig. 2
Phylogenetic analysis of ACE2 from humans and 18 other animals. The tree was constructed based on the complete amino acid sequences of ACE2s derived from humans and other animals by using the neighbor-joining (NJ) method with 1000 bootstrap. The accession numbers were as the same as Table 2. Bootstrap values above 50 were shown.

References

    1. Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192.
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
    1. WHO. .
    1. Chan J.F., Yuan S.F., Kok K.H., To K.K., Chu H., Yang J. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
    1. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
    1. Chinese C.D.C.
    1. Tatem A.J., Rogers D.J., Hay S.I. Global transport networks and infectious disease spread. Adv Parasitol. 2006;62:293–343.
    1. Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 doi: 10.1016/S0140-6736(20)30260-9.
    1. Cohen J.N., Normile D. New SARS-like virus in China triggers alarm. Science. 2020;367:234–235.
    1. Announcement from the Headquarter for novel coronavirus pneumonia prevention and control (No. 1) China National Health Commission; Beijing: 2020.
    1. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11:836–848.
    1. Su S., Wong G., Shi W.F., Liu J., Lai A.C., Zhou J.Y. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.
    1. Forni D., Cagliani R., Clerici M., Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25:35–48.
    1. Lipsitch M.C., Cohen T., Cooper B., Robins J.M., Ma S., James L. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300:1966–1970.
    1. Wallinga J., Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004;160:509–516.
    1. Lin Q., Chiu A.P., Zhao S., He D. Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia. Stat Methods Med Res. 2018;27:1968–1978.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Chan K.H., Peiris J.S., Lam S.Y., Poon L.L., Yuen K.Y., Seto W.H. The effects of temperature and relative humidity on the viability of the SARS coronavirus. Adv Virol. 2011;7:734690.
    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 doi: 10.1038/s41586-020-2012-7.
    1. Hoffmann M., Kleine W.H., Krüger N., Müller M. 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells.
    1. Zhao Y., Zhao Z.X., Wang Y.J., Zhou Y.Q., Ma Y., Zuo W. 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov.
    1. Zhang H., Kang Z.J., Gong H.Y., Xu D., Wang J., Li Z.F. 2020. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes.
    1. Wu F., Zhao S., Bin Y., Chen Y.M., Wang W., Song Z.G. A new coronavirus associated with human respiratory disease in China. Nature. 2020 doi: 10.1038/s41586-020-2008-3.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 doi: 10.1016/S0140-6736(20)30251-8.
    1. Hu B., Zeng L.P., Yang X.L., Ge X.Y., Zhang W., Li B. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13
    1. Letko M.M.V. 2020. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV.
    1. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020 doi: 10.1128/JVI.00127-20.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001316.
    1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
    1. Guan Y., He B.J., Liu Y.Q., Zhuang X.L., Zhuang Z.X., Cheung C.L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278.
    1. Ge X.Y., Li J., Yang X.L., Chmura A.A., Zhu G., Epstein J.H. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538.
    1. Azhar E.I., El-Kafrawy S.A., Farraj S.A., Hassan A.M., Al-Saeed M.S., Hashem A.M. Evidence for camel-to-human transmission of MERS Coronavirus. N Engl J Med. 2014;370:2499–2505.
    1. Kupferschmidt K. The camel connection. Science. 2014;343:1422–1425.
    1. Chinese I. .
    1. Emery S.L., Erdman D.D., Bowen M.D., Newton B.R., Winchell J.M., Meyer R.F. Real-time reverse transcription-polymerase chain reaction assay for SARSassociated coronavirus. Emerg Infect Dis. 2004;10:311–316.
    1. Gaunt E.R., Hardie A., Claas E.C., Simmonds P., Templeton K.E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48:2940–2947.
    1. Xu Z.J., Peng C., Shi Y.L., Zhu Z.D., Mu K.J., Wang X.Y. 2020. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation.
    1. Tai D. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. 2007;36:438–443.
    1. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.
    1. Nukoolkarn V.L., Lee V.S., Malaisree M., Aruksakulwong O., Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARSCoV 3CL(pro) inhibitors. J Theor Biol. 2008;254:861–867.
    1. Chong Y.P., Song J.Y., Seo Y.B., Choi J.P., Shin H.S., Team R.R. Antiviral treatment guidelines for middle east respiratory syndrome. Infect Chemother. 2015;47:212–222.
    1. Arabi Y.M., Alothman A., Balkhy H.H., Al-Dawood A., c S., Harbi S.A. Treatment of Middle East Respiratory Syndrome with a combination of lopinavirritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81.
    1. Wang M.L., Cao R., Zhang L., Yang X.L., Liu J., Xu M.Y. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren